



TITLE:

# Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma.

AUTHOR(S):

Matsumoto, Hisako; Niimi, Akio; Jinnai, Makiko; Nakaji, Hitoshi; Takeda, Tomoshi; Oguma, Tsuyoshi; Otsuka, Kojiro; ... Hirai, Toyohiro; Chin, Kazuo; Mishima, Michiaki

---

CITATION:

Matsumoto, Hisako ...[et al]. Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma.. *Respiration* 2011, 81(4): 311-317

ISSUE DATE:

2011-03

URL:

<http://hdl.handle.net/2433/197216>

RIGHT:

© 2010 S. Karger AG, Basel; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

**Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma**

Hisako Matsumoto, MD, PhD<sup>1)</sup>, Akio Niimi, MD, PhD<sup>1)</sup>, Makiko Jinnai, MD, PhD<sup>1)</sup>, Hitoshi Nakaji, MD<sup>1)</sup>, Tomoshi Takeda, MD, PhD<sup>1)</sup>, Tsuyoshi Oguma, MD<sup>1)</sup>, Kojiro Otsuka, MD<sup>1)</sup>, Hideki Inoue, MD<sup>1)</sup>, Masafumi Yamaguchi, MD, PhD<sup>1)</sup>, Hirofumi Matsuoka, MD<sup>1)</sup>, Isao Ito, MD, PhD<sup>1)</sup>, Toyohiro Hirai, MD, PhD<sup>1)</sup>, Kazuo Chin, MD, PhD<sup>2)</sup>, Michiaki Mishima, MD, PhD<sup>1)</sup>

1) Department of Respiratory Medicine, Kyoto University, Kyoto, Japan

2) Department of Respiratory Care and Sleep Control Medicine, Kyoto University, Kyoto, Japan

This work was conducted at the Department of Respiratory Medicine, Kyoto University, Kyoto, Japan

Short title: **Association of alveolar NO with pulmonary function in asthma**

Corresponding Author

Name: Hisako Matsumoto

Mailing address: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan

Telephone: 81-75-751-3830

Fax: 81-75-751-4643

E-mail: [hmatsumo@kuhp.kyoto-u.ac.jp](mailto:hmatsumo@kuhp.kyoto-u.ac.jp)

**Key Words:** airway reversibility, alveolar NO, asthma, impulse oscillometry system, peripheral airway dysfunction, trumpet model with axial diffusion

## 25 Abstract

26 **Background:** Inflammation of peripheral airways is implicated in the pathophysiology  
27 of severe asthma. However, contributions of peripheral airway inflammation to airway  
28 caliber/function in patients with stable asthma, including those with mild to moderate  
29 disease, remain to be confirmed.

30 **Objectives:** To determine whether peripheral airway inflammation affects airway  
31 function in patients with asthma.

32 **Methods:** In 70 patients with mild to severe asthma, alveolar nitric oxide (CANO<sub>(TMAD)</sub>)  
33 levels were examined as a noninvasive biomarker of peripheral airway/alveolar  
34 inflammation. CANO<sub>(TMAD)</sub> and maximal NO flux in the airway compartment, J'awNO,  
35 were estimated with a model that incorporated trumpet shaped airways and axial  
36 diffusion using exhaled NO output at different flow rates. Measures of pulmonary  
37 function were then assessed by spirometry and an impulse oscillometry system, and  
38 their bronchodilator reversibility was examined. **Results:** CANO<sub>(TMAD)</sub> levels were not  
39 correlated with pre- or post-bronchodilator spirometric values, but were significantly  
40 associated with pre-bronchodilator reactance at low frequency (Xrs5) ( $\rho=-0.31$ ,  
41  $p=0.011$ ), integrated area of low-frequency Xrs (AX) ( $\rho=0.35$ ,  $p=0.003$ ) and negative  
42 frequency dependence of resistance (Rrs5-Rrs20) ( $\rho=0.35$ ,  $p=0.004$ ). Furthermore,  
43 CANO<sub>(TMAD)</sub> levels were associated with bronchodilator reversibility of FEV<sub>1</sub>, FEF<sub>25-75%</sub>,  
44 Xrs5, and AX ( $\rho=0.35$ ,  $\rho=0.31$ ,  $\rho=-0.24$ ,  $\rho=-0.31$ , respectively;  $p\leq 0.05$  for all).  
45 No variables were related to J'awNO. **Conclusions:** Elevated CANO<sub>(TMAD)</sub>, but not  
46 J'awNO, partly reflects reversible airway obstruction originating in the peripheral airway.  
47 These findings indicate the involvement of peripheral airway inflammation in  
48 physiological abnormalities in asthma.

49

50    **Abbreviations**

51    AX: integrated area of low-frequency reactance

52    BD: bronchodilator

53    C<sub>ANO</sub>: alveolar fraction of exhaled NO

54    C<sub>ANO(TMAD)</sub>: alveolar fraction of exhaled NO adjusted for trumpet shaped airways and  
55    axial diffusion

56    FEF<sub>25-75%</sub>: mid forced expiratory flow

57    FeNO: fraction of exhaled NO

58    FeNO<sub>50</sub>: FeNO at 50 ml/sec

59    ICS: inhaled corticosteroids

60    IOS: impulse oscillometry system

61    J'<sub>awNO</sub>: bronchial NO maximal flux adjusted for trumpet shaped airways and axial  
62    diffusion

63    NO: nitric oxide

64    R<sub>rs</sub>: resistance of the total respiratory system

65    R<sub>rs5</sub>: R<sub>rs</sub> at 5 Hz

66    R<sub>rs20</sub>: R<sub>rs</sub> at 20 Hz

67    X<sub>rs</sub>: reactance of the total respiratory system

68    X<sub>rs5</sub>: X<sub>rs</sub> at 5 Hz

69

## Introduction

Asthma is a chronic inflammatory disorder involving proximal airways as well as small peripheral airways [1-4]. Nitric oxide (NO) is a well-established noninvasive biomarker of inflammation in asthmatic airways [5]. Recently, the alveolar fraction of exhaled NO (C<sub>ANO</sub>) has been introduced to assess inflammation of peripheral airway/alveolar regions [6]. This variable has received renewed interest as a noninvasive tool for both adults [7] and children [8]. Although C<sub>ANO</sub> is mathematically derived from NO output measured at multiple flow rates, a study by Berry and colleagues has shown a strong correlation between C<sub>ANO</sub> levels and eosinophil counts in bronchoalveolar lavage fluid [9], suggesting that C<sub>ANO</sub> may reflect peripheral airway/alveolar inflammation. Moreover, two trumpet models with axial diffusion have recently been developed to correct the effect of axial contamination by small airway NO diffusion on C<sub>ANO</sub> [10, 11]. This new parameter, C<sub>ANO(TMAD)</sub>, precludes overestimating actual NO production in the alveolar region.

Peripheral airway dysfunction or the degree of air trapping is associated with recurrent exacerbations of severe asthma [12] or with disease severity [13]. Effective prevention of peripheral airway dysfunction requires an understanding of the contribution of peripheral airway inflammation to airway dysfunction. However, such a contribution has been confirmed only for severe refractory asthma [14, 15]. Because peripheral airway inflammation is not limited to patients with severe disease [1], we hypothesized that sustained inflammation in the peripheral airway or alveolar region may be linked to airway dysfunction in the general population of patients with asthma. In this study, we measured C<sub>ANO(TMAD)</sub>, pulmonary function and pulmonary function

reversibility in response to treatment with a bronchodilator (BD) for patients with asthma ranging from mild intermittent to severe persistent. Using an impulse oscillometry system (IOS) [16] [17], we examined negative frequency dependence and low frequency reactance that could be proxies for peripheral airway function.

## Methods

### Subjects

This cross-sectional study was conducted at the outpatient asthma and cough clinic of Kyoto University Hospital from January through December 2007. We examined NO levels at different flow rates (50, 100, and 200 ml/s) in 75 adults with stable asthma. The inclusion criteria were as follows: 1) a diagnosis of asthma as defined by the American Thoracic Society [18] on the basis of a history of recurrent episodes of wheezing and chest tightness with or without cough; 2) confirmation of airway hyperresponsiveness on past evaluations; 3) regular attendance at our clinic for >3 months; 4) no exacerbation of asthma during the last 4 weeks; 5) no changes in treatment during the last 4 weeks; 6) non-smokers or ex-smokers who had smoked <10 pack-years but had not smoked for >1 year; 7) no evidence of other respiratory diseases on chest X-ray findings. Severity was defined according to the step classification of the 2004 version of the Global Initiative for Asthma guidelines [19]. Three patients with step 2 asthma were treated with leukotriene receptor antagonists because they refused to use inhaled corticosteroids (ICS). To examine patients with persistent airway inflammation, we measured NO levels at higher flows in patients with fraction of exhaled NO (FeNO) at 50 ml/sec (FeNO<sub>50</sub>) values  $\geq$  25 ppb [5]. The ethics committee of our institution approved the study protocol, and written informed consent was

obtained from each participant.

## Measurement of NO and calculation of $C_{ANO(TMAD)}$ and bronchial NO maximal flux

NO levels were measured with a chemiluminescence analyzer (NOA 280, Sievers, Boulder, CO, USA) according to current guidelines, apart from the expiratory flow rate [20]. The analyzer was calibrated daily with gas without NO generated by exposing ambient air to NO scavengers and a standard concentration of 640 ppb NO. The lower detection limit for NO was 2 ppb. The signal output from the NO analyzer was fed to a computer data acquisition program, and concentrations were measured using a data analysis program (NOA Analysis™ Software, Sievers, Boulder, CO, USA). Seated subjects inserted a mouthpiece, inhaled orally to total lung capacity, exhaled immediately against a resistance, and maintained mouth pressure at 20 cmH<sub>2</sub>O, displayed on a pressure gauge. The steady-state NO plateau was taken as the FeNO value. By varying expiratory resistances, we measured FeNO levels at three expiratory flows of 50, 100 and 200 ml/s in that order. If an adequate NO plateau was not reached at 200 ml/s, patients were then instructed to exhale at a flow of 150 ml/s instead (n=4).

$C_{ANO(TMAD)}$  was estimated using a model recently developed by Condorelli and colleagues that incorporated trumpet shaped airways and axial diffusion [10] rather than simply assuming that the lung was comprised of two separate regions with a rigid airway compartment and a well mixed expansible compartment [6]. The equation used was the following:  $C_{ANO(TMAD)} = \text{slope} - \text{intercept}/740$ . The slope and intercept of this equation were determined from a linear regression line after plotting NO output (i.e., exhaled NO level times expiratory flow) as a function of expiratory flow. When

CANO(TMAD) values were < zero, they were assigned a value of zero. Bronchial NO maximal flux ( $J'_{awNO}$ ), a marker of inflammation in the airway compartment, was also determined by multiplying the intercept by 1.7. Because this trumpet model with axial diffusion was developed based on the assumption that NO flux from the airway tree was a constant and this simplified equation was valid at an expiratory flow rate between 100 ml/s and 250 ml/s, we applied FeNO levels at 100 ml/s and 200 ml/s to obtain a linear regression line between NO output and exhalation flow. Five patients whose results had negative slopes were excluded from further analysis [10].

### **Pulmonary function tests**

After NO measurements, subjects underwent pre- and post-BD (i.e., inhalation of 200  $\mu$ g salbutamol) pulmonary function testing. Respiratory impedance was measured by IOS followed by spirometric testing. Reversibility of the impedance and spirometric values was calculated by: (post-BD value minus pre-BD value)/pre-BD value.

Spirometry was performed according to the standards of the American Thoracic Society [21] using a ChestGraph HI-701 spirometer (Chest, Tokyo, Japan). FEV<sub>1</sub> and mid forced expiratory flow (FEF<sub>25-75%</sub>) were determined.

Respiratory impedance was measured using a Jaeger MasterScreen, IOS<sup>TM</sup> (Erich Jaeger, Hoechberg Germany) that met standard recommendations [22]. The IOS is different from the classical forced oscillation technique by the use of an impulse rather than a pseudorandom noise signal and in data processing. In brief, rectangular mechanical impulses containing a continuous power spectrum ranging from 0 to 100 Hz, generated by a loudspeaker at intervals of 0.2 s, were applied to the respiratory system



through a mouthpiece during tidal breathing. The resulting pressure and flow signals were measured next to the mouthpiece, and were analyzed for amplitude and phase differences using a fast Fourier transform to determine resistance (Rrs) and reactance (Xrs) of the total respiratory system. To reduce loss of energy in the upper airways, the chin and cheeks were supported by the subjects' hands. As proxies for peripheral airway function [16] [17] [23] [24], we used the negative frequency dependence of Rrs between 5 and 20 Hz (Rrs5-Rrs20), Xrs at 5 Hz (Xrs5), and reactance area (AX) that is the integral of Xrs from 5 Hz to the resonant frequency at which Xrs crosses zero. Rrs at 20 Hz (Rrs20) was used as a measure of proximal airway resistance, as oscillatory pressure components at frequencies  $\geq 20$  Hz are thought to be damped out before reaching the peripheral airways [16].

### Statistical analysis

Data were analyzed using GraphPad Prism 4.00 (GraphPad Software, Inc., La Jolla, CA, USA) and StatView software 5.0 (SAS Institute Inc, Cary, NC, USA). When data were normally distributed, linear regression analysis was used. Otherwise, Spearman's rank-correlation test was used. The correlation coefficient from linear regression analysis is denoted as R, whereas Spearman's correlation coefficient is given as rho. Results are expressed as means  $\pm$  SDs or medians (ranges). We considered p values of  $\leq 0.05$  to indicate statistical significance.

## Results

### Patients' characteristics

The characteristics of the 70 subjects are shown in Table 1. Measures of pulmonary function and FeNO<sub>50</sub> of the 70 subjects did not differ significantly from those of the 5 patients whose slopes were negative (data not shown).

### Correlations between patients' characteristics and C<sub>ANO</sub>(TMAD) or bronchial flux

Patients with more severe asthma showed a trend for higher J'awNO levels than those with milder disease ( $\rho=0.23$ ,  $p=0.056$ ), but not for C<sub>ANO</sub>(TMAD) levels ( $\rho=0.17$ ,  $p=0.17$ ). The presence of atopy, rhinitis and smoking history were not associated with C<sub>ANO</sub>(TMAD) or J'awNO (data not shown).

### Correlations of C<sub>ANO</sub>(TMAD) or bronchial flux with pre- and post-BD pulmonary function measures

The associations of C<sub>ANO</sub>(TMAD) and J'awNO with pulmonary function measures are summarized in Table 2. Correlations of pulmonary function measures with FeNO<sub>50</sub> that were strongly correlated with J'awNO levels ( $\rho=0.83$ ,  $p<0.0001$ ) are also shown in this table. There was no association of C<sub>ANO</sub>(TMAD) with pre-BD %FEV<sub>1</sub>, %FEF<sub>25-75</sub>%, or Rrs20. C<sub>ANO</sub>(TMAD) was significantly associated with pre-BD Rrs5-Rrs20, Xrs5, and AX (Fig 1). The association between Xrs5 and C<sub>ANO</sub>(TMAD) remained significant even when two obvious outliers (one with the highest Xrs5 and another with the lowest Xrs5) were excluded ( $\rho=-0.36$ ,  $p=0.003$   $n=68$ ). There was no association between C<sub>ANO</sub>(TMAD) and any measure of post-BD pulmonary function. J'awNO was not related to any indices of pulmonary function.

211 Measures of pre-BD Rrs5-Rrs20, Xrs5, and AX were moderately to strongly  
212 correlated with each other ( $|\rho|$  ranged between 0.75 and 0.93,  $p < 0.0001$ ). These  
213 measures of pre-BD IOS were correlated with pre-BD %FEV<sub>1</sub> ( $|\rho|$  ranged between  
214 0.33 and 0.40,  $p < 0.01$ ).

215

216 **Correlations between CANO(TMAD) or bronchial flux and reversibility of pulmonary**  
217 **function measures**

218 Reversibilities of FEV<sub>1</sub> and FEF<sub>25-75%</sub>, as well as of Xrs5 and AX, were significantly  
219 associated with CANO(TMAD) (Table 2). J'awNO was not related to any indices of  
220 reversibility.

221 Reversibilities of FEV<sub>1</sub>, FEF<sub>25-75%</sub> Xrs5 and AX were associated with pre-BD  
222 levels; reversibility of FEV<sub>1</sub> was correlated with the pre-BD FEV<sub>1</sub> level ( $R = -0.56$ ,  
223  $p < 0.0001$ ); for %FEF<sub>25-75%</sub>,  $\rho = -0.25$ ,  $p = 0.042$ ; for Xrs5,  $\rho = 0.48$ ,  $p < 0.0001$ ; for AX,  
224  $\rho = -0.40$ ,  $p = 0.001$ .

225

226

## 227 Discussion

228 To the best of our knowledge, this is the first study to demonstrate that in adult patients  
229 with stable asthma,  $C_{ANO(TMAD)}$ , but not  $J'_{awNO}$ , is significantly associated with Rrs5-  
230 Rrs20, Xrs5, and AX levels, which are thought to reflect peripheral airway function.  
231 Our novel findings are that the increase in  $C_{ANO(TMAD)}$  associates with greater  
232 reversibility of FEV<sub>1</sub>, FEF<sub>25-75%</sub>, Xrs5 and AX in response to treatment with a BD.  
233 These findings suggest that peripheral airway/alveolar inflammation may contribute to  
234 reversible airway obstruction originating in the peripheral airway.

235 Before the introduction of  $C_{ANO(TMAD)}$ ,  $C_{ANO}$  had been used as a reasonably well  
236 validated marker of inflammation of the peripheral airway/alveolar region [9].  
237 Histological studies have suggested that peripheral airway inflammation has a similar or  
238 greater impact on disease severity than does proximal airway inflammation [1, 23, 24].  
239 Studies examining  $C_{ANO}$  have drawn similar conclusions;  $C_{ANO}$  in refractory asthma is  
240 significantly greater than that in mild to moderate asthma [9], and patients with oral  
241 steroid-dependent asthma have higher  $C_{ANO}$  levels than patients with mild-to-moderate  
242 or severe asthma [14] [25]. In this study,  $J'_{awNO}$  showed a trend toward increased  
243 values in patients with more severe asthma than those with milder disease. However,  
244 when  $C_{ANO(TMAD)}$  was determined using a trumpet model with axial diffusion that  
245 estimated NO concentrations exiting the respiratory bronchioles and alveolar region,  
246  $C_{ANO(TMAD)}$  was not correlated with disease severity, which is consistent with a recent  
247 finding by Mahut et al [26]. Given that  $C_{ANO}$  is not adjusted for NO axial diffusion  
248 from conducting airways and could be more contaminated by small airway NO  
249 diffusion than  $C_{ANO(TMAD)}$ , this discrepancy between previous findings with  $C_{ANO}$  and  
250 those with  $C_{ANO(TMAD)}$  in this study may indicate that small airway inflammation

influences asthma severity to a greater extent than the actual alveolar inflammation. Indeed, a histological study of severe asthmatics showed that small airways with perimeters less than 6 mm were the most significantly infiltrated by inflammatory cells across the entire airway tree, from the large airways to the alveolar tissue [23].

Van Veen and colleagues found significant correlations of  $C_{ANO}$  with peripheral airway obstruction, as assessed by residual volume, functional residual capacity and closing capacity [14], in patients with severe asthma. However, when patients with mild-to-moderate asthma were included, these correlations disappeared, and only a significant association between  $C_{ANO}$  and the slope of the single breath nitrogen washout curve remained. Although  $C_{ANO}$  was correlated with  $FEF_{25-75\%}$  in children with refractory asthma [15],  $C_{ANO}$  was not correlated with  $FEF_{50\%}$ ,  $FEF_{25\%}$ , or residual volume in adults with asthma [25]. These studies provide little or no evidence of a link between peripheral airway inflammation and dysfunction in the population of adults with asthma.

In the current study, however,  $C_{ANO(TMAD)}$  was modestly, but significantly associated with small airway reactance/capacitance ( $X_{rs5}$ ,  $AX$ ) and negative frequency dependence of airway resistance ( $R_{rs5}$ - $R_{rs20}$ ). These variables obtained by IOS, a non-invasive and effort-independent tool, have been proposed as relevant and sensitive indices of peripheral airway function [16] [17] [23] [28] [27] [28]. Previous oscillation studies have demonstrated that as peripheral resistance increases, the resistance at low frequencies increases compared to the higher frequencies, thereby resulting in greater negative frequency dependence of  $R_{rs}$  [16, 29].  $X_{rs}$  at low frequency is also considered to reflect the capacitative properties of peripheral airways and to detect peripheral airway narrowing [30]. In our recent study of patients with asthma,  $R_{rs5}$ - $R_{rs20}$  and  $AX$ ,

but not Rrs20, are significantly associated with residual volume [23]. Another recent long-term study of controller therapy for pediatric asthma also demonstrates that AX may be sensitive to changes in peripheral airway function [27]. The nature of these indices of IOS may support our premise that Rrs5-Rrs20, Xrs, and, particularly, AX may reflect peripheral airway function. However, as discussed below, the data should be interpreted with caution because IOS indices are indirect measures, and no associations of IOS indices with pathological changes have been demonstrated thus far.

Airway variability is another feature of asthma, implying instability of the disease. Endobronchial and transbronchial biopsy studies of nocturnal asthma have demonstrated a significant contribution of peripheral airway inflammation to nocturnal decrement of pulmonary function as compared with proximal airway inflammation [31]. In studies of pediatric asthma, higher FeNO levels are associated with greater FEV<sub>1</sub> reversibility [32-34]. Tsuburai and colleagues show associations between FeNO levels and FEV<sub>1</sub> reversibility in adult asthmatics with airflow limitation, but not in those without airflow limitation [35]. Our study of adult asthmatics extended the previous findings by showing that smoldering inflammation in the peripheral airway/alveolar compartment is responsible for greater BD response in FEV<sub>1</sub>, FEF<sub>25-75%</sub>, Xrs5, and AX, and that reversibility to a BD depends on the degree of pre-BD obstruction. Given that C<sub>ANO(TMAD)</sub> was correlated with pre-BD Xrs5 and AX, but not with FEV<sub>1</sub> or FEF<sub>25-75%</sub> values, we speculate that peripheral airway/alveolar inflammation may contribute to reversible airway obstruction originating in the peripheral airway.

In sharp contrast to C<sub>ANO(TMAD)</sub>, bronchial NO flux (i.e. J<sub>awNO</sub> levels) was not correlated with any indices of pulmonary function and FeNO<sub>50</sub> was only correlated with reversibility of Xrs5, which was consistent with other studies [7] [36]. This discrepancy

299 between  $C_{ANO(TMAD)}$  and  $J'_{awNO}$  could be attributed to differences in their responses to  
300 ICS treatment. When patients are treated with an ICS,  $J'_{awNO}$  readily decreases,  
301 whereas  $C_{ANO}$  is resistant to them [37]. Therefore, we speculate that any correlation of  
302  $J'_{awNO}$  or  $FeNO_{50}$  with pulmonary function might have been modified by ICS treatment.  
303 Indeed, in steroid naïve patients, exhaled NO levels are correlated with airway  
304 hyperresponsiveness [38], asthma symptom scores [39], or with bronchodilator response  
305 [34], whereas such correlations disappear in patients on ICS. Intriguingly, a recent study  
306 shows significant associations between exhaled NO levels and  $FEV_1$  or bronchodilator  
307 responses in pediatric asthmatics receiving ICS treatments when they are classified  
308 according to their ICS doses [40], which may suggest that stratifying patients by ICS  
309 doses could provide deeper insights into the roles of exhaled NO in patients on ICS.

310 The role of  $C_{ANO(TMAD)}$  in peripheral airway obstruction should not be  
311 overestimated because the associations were modest; elevated  $C_{ANO(TMAD)}$  is not a  
312 strong indicator for low  $Xrs5$  or increased AX. Also, IOS variables were not compared  
313 with closing volume or closing capacity, other proxy measures of peripheral airway  
314 obstruction. As mentioned above, IOS measurements have several limitations and  
315 should be interpreted cautiously [16] [17] because of issues that include artifact effects  
316 of upper airway compliance and leaks at the mouthpiece. Increases in  $Rrs5$ - $Rrs20$  may  
317 imply heterogeneity of peripheral airway narrowing in addition to an absolute increase  
318 in resistance [41].  $Xrs5$  is relatively noise-sensitive, whereas AX is less so. Resistance  
319 and reactance in the peripheral airway may indicate different properties, given that pre-  
320 BD values of  $Rrs5$ - $Rrs20$  were not correlated with reversibility to a BD, whereas pre-  
321 BD values of AX and  $Xrs5$  were, although precise mechanisms underlying this  
322 discrepancy are unknown.

We may have missed some patients with normal  $\text{FeNO}_{50}$  and high  $\text{CANO}_{(\text{TMAD})}$  by excluding those with  $\text{FeNO}_{50} < 25$  ppb. When pediatric patients with asthma are grouped based on their  $\text{J}'_{\text{awNO}}$  and  $\text{CANO}_{(\text{TMAD})}$  levels, Puckett et al find that 11% of the patients have normal  $\text{J}'_{\text{awNO}}$  and high  $\text{CANO}_{(\text{TMAD})}$  levels [42]. However, when we examined another 21 patients with stable asthma who had  $\text{FeNO}_{50} < 25$  ppb, their ratios of  $\text{CANO}_{(\text{TMAD})}$  levels to  $\text{FeNO}_{50}$  levels did not differ from those of the currently studied population (data not shown), suggesting that patients with normal  $\text{FeNO}_{50}$  and high  $\text{CANO}_{(\text{TMAD})}$  are not commonly observed in our patient population. Therefore, we believe that the possibility of missing patients with normal  $\text{FeNO}_{50}$  and high  $\text{CANO}_{(\text{TMAD})}$  may not have severely affected our findings.

Five patients were excluded from the analysis because their results had negative slopes in plots of NO output vs. expiratory flow between 100 ml/s and 200 ml/s. NO axial diffusion from the airway tree increases as bronchial flux increases and its relative impact over NO conductive transport exiting the alveolar region is greater at lower expiratory flows [10]. Therefore, the negative slopes for five patients may indicate that, in these patients, the relative impact of NO axial diffusion on NO output with exhalation flows around 100 ml/s might have remained either because of increased bronchial reflux or because of relatively small NO production in the alveolar region. Measurements with higher expiratory flows would have been desirable, but it was difficult for our patients to obtain a steady-state NO plateau with higher flows, such as at 250 ml/s or 300 ml/s. Despite these limitations, our findings support the superiority of a multiple flow technique to a conventional single flow measurement, as the former provides information on peripheral airway/alveolar inflammation.

In conclusion, inflammation in the peripheral airway/alveolar region as



347 assessed by  $CANO^{(TMAD)}$  partly contributes to the development of peripheral airway  
348 obstruction and to reversibility of pulmonary function in response to a bronchodilator.  
349 Monitoring peripheral airway/alveolar inflammation may provide higher-quality  
350 information for patients with asthma.  
351  
352

353     **The authors have no conflicts of interest to disclose.**

354

355

## References

- 1 Carroll N, Cooke C, James A: The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. *Eur Respir J* 1997;10:292-300.
- 2 Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC: Inflammation of small airways in asthma. *J Allergy Clin Immunol* 1997;100:44-51.
- 3 Kraft M: The distal airways: Are they important in asthma? *Eur Respir J* 1999;14:1403-1417.
- 4 Verbanck S, Schuermans D, Noppen M, Van Muylem A, Paiva M, Vincken W: Evidence of acinar airway involvement in asthma. *Am J Respir Crit Care Med* 1999;159:1545-1550.
- 5 Ats workshop proceedings: Exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. *Proc Am Thorac Soc* 2006;3:131-145.
- 6 Tsoukias NM, George SC: A two-compartment model of pulmonary nitric oxide exchange dynamics. *J Appl Physiol* 1998;85:653-666.
- 7 Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N: Alveolar and airway sites of nitric oxide inflammation in treated asthma. *Am J Respir Crit Care Med* 2004;170:737-741.
- 8 Paraskakis E, Brindicci C, Fleming L, Krol R, Kharitonov SA, Wilson NM, Barnes PJ, Bush A: Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. *Am J Respir Crit Care Med* 2006;174:260-267.
- 9 Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID: Alveolar nitric oxide in adults with asthma: Evidence of distal lung inflammation in refractory asthma. *Eur Respir J* 2005;25:986-

- 380 991.
- 381 10 Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC: A simple technique
- 382 to characterize proximal and peripheral nitric oxide exchange using constant flow
- 383 exhalations and an axial diffusion model. *J Appl Physiol* 2007;102:417-425.
- 384 11 Kerckx Y, Michils A, Van Muylem A: Airway contribution to alveolar nitric
- 385 oxide in healthy subjects and stable asthma patients. *J Appl Physiol* 2008;104:918-924.
- 386 12 in 't Veen JC, Beekman AJ, Bel EH, Sterk PJ: Recurrent exacerbations in severe
- 387 asthma are associated with enhanced airway closure during stable episodes. *Am J*
- 388 *Respir Crit Care Med* 2000;161:1902-1906.
- 389 13 Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M,
- 390 Matsuoka H, Jinnai M, Muro S, Chin K, Mishima M: Role of small airways in asthma:
- 391 Investigation using high-resolution computed tomography. *J Allergy Clin Immunol*
- 392 2006;118:1019-1025.
- 393 14 van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH: Alveolar nitric
- 394 oxide versus measures of peripheral airway dysfunction in severe asthma. *Eur Respir J*
- 395 2006;27:951-956.
- 396 15 Mahut B, Delclaux C, Tillie-Leblond I, Gosset P, Delacourt C, Zerah-Lancner F,
- 397 Harf A, de Blic J: Both inflammation and remodeling influence nitric oxide output in
- 398 children with refractory asthma. *J Allergy Clin Immunol* 2004;113:252-256.
- 399 16 Goldman MD, Saadeh C, Ross D: Clinical applications of forced oscillation to
- 400 assess peripheral airway function. *Respir Physiol Neurobiol* 2005;148:179-194.
- 401 17 Smith HJ, Reinhold P, Goldman MD: Forced oscillation technique and impulse
- 402 oscillometry. *Eur Respir Mon* 2005;31:72-105.
- 403 18 Standards for the diagnosis and care of patients with chronic obstructive

404 pulmonary disease (COPD) and asthma. This official statement of the American  
405 Thoracic Society was adopted by the ATS board of directors, November 1986. *Am Rev*  
406 *Respir Dis* 1987;136:225-244.

407 19 Global strategy for asthma management and prevention. Publication #02-3659.  
408 Bethesda, MD. National Institute of Health/National Heart, Lung, and Blood Institute;  
409 updated 2004

410 20 ATS/ERS recommendations for standardized procedures for the online and  
411 offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide,  
412 2005. *Am J Respir Crit Care Med* 2005;171:912-930.

413 21 Standardization of spirometry, 1994 update. American Thoracic Society. *Am J*  
414 *Respir Crit Care Med* 1995;152:1107-1136.

415 22 Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F:  
416 The forced oscillation technique in clinical practice: Methodology, recommendations  
417 and future developments. *Eur Respir J* 2003;22:1026-1041.

418 23 Balzar S, Wenzel SE, Chu HW: Transbronchial biopsy as a tool to evaluate  
419 small airways in asthma. *Eur Respir J* 2002;20:254-259.

420 24 Wenzel S: Severe asthma in adults. *Am J Respir Crit Care Med* 2005;172:149-  
421 160.

422 25 Brindicci C, Ito K, Barnes PJ, Kharitonov SA: Differential flow analysis of  
423 exhaled nitric oxide in patients with asthma of differing severity. *Chest* 2007;131:1353-  
424 1362.

425 26 Mahut B, Trinquart L, Le Bourgeois M, Becquemin MH, Beydon N, Aubourg F,  
426 Jala M, Bidaud-Chevalier B, Dinh-Xuan AT, Randrianarivelo O, Denjean A, de Blic J,  
427 Delclaux C: Multicentre trial evaluating alveolar no fraction as a marker of asthma

- 428 control and severity. *Allergy* 2010;65:636-644.
- 429 27 Larsen GL, Morgan W, Heldt GP, Mauger DT, Boehmer SJ, Chinchilli VM,  
430 Lemanske RF, Jr., Martinez F, Strunk RC, Szefer SJ, Zeiger RS, Taussig LM,  
431 Bacharier LB, Guilbert TW, Radford S, Sorkness CA: Impulse oscillometry versus  
432 spirometry in a long-term study of controller therapy for pediatric asthma. *J Allergy*  
433 *Clin Immunol* 2008;123:861-867.
- 434 28 Takeda T, Oga T, Niimi A, Matsumoto H, Ito I, Yamaguchi M, Matsuoka H,  
435 Jinnai M, Otsuka K, Oguma T, Nakaji H, Chin K, Mishima M: Relationship between  
436 small airway function and health status, dyspnea and disease control in asthma.  
437 *Respiration* 2009;Epub ahead of print
- 438 29 Clement J, Landser FJ, Van de Woestijne KP: Total resistance and reactance in  
439 patients with respiratory complaints with and without airways obstruction. *Chest*  
440 1983;83:215-220.
- 441 30 Kolsum U, Borrill Z, Roy K, Starkey C, Vestbo J, Houghton C, Singh D:  
442 Impulse oscillometry in COPD: Identification of measurements related to airway  
443 obstruction, airway conductance and lung volumes. *Respir Med* 2008
- 444 31 Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ: Alveolar tissue  
445 inflammation in asthma. *Am J Respir Crit Care Med* 1996;154:1505-1510.
- 446 32 Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW: Correlation  
447 between reversibility of airway obstruction and exhaled nitric oxide levels in children  
448 with stable bronchial asthma. *Pediatr Pulmonol* 2000;30:385-392.
- 449 33 Silvestri M, Sabatini F, Sale R, Defilippi AC, Fregonese L, Battistini E, Biraghi  
450 MG, Rossi GA: Correlations between exhaled nitric oxide levels, blood eosinophilia,  
451 and airway obstruction reversibility in childhood asthma are detectable only in atopic

- 452 individuals. *Pediatr Pulmonol* 2003;35:358-363.
- 453 34 Puckett JL, Taylor RW, Leu SY, Guijon OL, Aledia AS, Galant SP, George SC:  
454 An elevated bronchodilator response predicts large airway inflammation in mild asthma.  
455 *Pediatr Pulmonol* 2010;45:174-181.
- 456 35 Tsuburai T, Tsurikisawa N, Taniguchi M, Morita S, Ono E, Oshikata C, Ohtomo  
457 M, Maeda Y, Ikehara K, Akiyama K: The relationship between exhaled nitric oxide  
458 measured with an off-line method and airway reversible obstruction in Japanese adults  
459 with asthma. *Allergol Int* 2007;56:37-43.
- 460 36 Shin HW, Rose-Gottron CM, Cooper DM, Newcomb RL, George SC: Airway  
461 diffusing capacity of nitric oxide and steroid therapy in asthma. *J Appl Physiol*  
462 2004;96:65-75.
- 463 37 Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E:  
464 Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma.  
465 *Eur Respir J* 2001;18:635-639.
- 466 38 Dupont LJ, Rochette F, Demedts MG, Verleden GM: Exhaled nitric oxide  
467 correlates with airway hyperresponsiveness in steroid-naïve patients with mild asthma.  
468 *Am J Respir Crit Care Med* 1998;157:894-898.
- 469 39 Tsujino I, Nishimura M, Kamachi A, Makita H, Munakata M, Miyamoto K,  
470 Kawakami Y: Exhaled nitric oxide--is it really a good marker of airway inflammation in  
471 bronchial asthma? *Respiration* 2000;67:645-651.
- 472 40 Mahut B, Trinquart L, Bokov P, Peiffer C, Delclaux C: The link between  
473 exhaled NO and bronchomotor tone depends on the dose of inhaled steroid in asthma.  
474 *Respir Med* 2010;104:945-950.
- 475 41 Kaczka DW, Ingenito EP, Suki B, Lutchen KR: Partitioning airway and lung

476 tissue resistances in humans: Effects of bronchoconstriction. J Appl Physiol  
477 1997;82:1531-1541.

478 42 Puckett JL, Taylor RW, Leu SY, Guijon OL, Aledia AS, Galant SP, George SC:  
479 Clinical patterns in asthma based on proximal and distal airway nitric oxide categories.  
480 Respir Res 2010;11:47.

481

482

483



484

485 **Figure legend**

486 Figure 1. Relationships between  $CA_{NO(TMAD)}$  levels and pre-bronchodilator Xrs5 (left)  
487 and Rrs5-Rrs20 (right).

488

Table 1. Patients' characteristics (n=70)

Gender, M/F	33/37
Age, yr	57.4 ± 15.6
Disease duration, yr	12.2 ± 10.4
Asthma severity*, 1/2/3/4	2/35/17/16
Atopy, positive <sup>†</sup> , %	66
IgE, IU	190 (5, 6800)
Ex smoker, %	33
Sinusitis/rhinitis, %	66
Daily dose of ICS <sup>‡</sup> , µg	400 (0, 1600)
%FEV <sub>1</sub> , %	89.4 ± 16.5
%FEF <sub>25-75%</sub> , %	57.4 ± 26.8
Rrs20, kPa·s·L <sup>-1</sup>	0.32 ± 0.11
Rrs5-Rrs20, kPa·s·L <sup>-1</sup>	0.06 (-0.03, 0.43)
Xrs5, kPa·s·L <sup>-1</sup>	-0.13 (-0.56, 0.17)
AX, kPa·s·L <sup>-1</sup>	0.44 (0.01, 5.51)
FeNO <sub>50</sub> , ppb	44.9 (25.0, 224.4)
J'awNO, pl·s <sup>-1</sup>	3638 (0, 15300)
CANO(TMAD), ppb	3.9 (0, 34.9)

\*According to the Global Initiative for Asthma guidelines [19]. <sup>†</sup>Considered atopic when one or more specific IgE antibodies against house dust mite, cat dander, dog dander, molds, weed, cedar pollen, or grass pollen were positive. <sup>‡</sup>Equivalent dose of fluticasone. ICS = inhaled corticosteroids, Rrs20 = resistance of the total respiratory system at 20 Hz, Rrs5 = Rrs at 5 Hz, Xrs5 = reactance at 5 Hz, AX = area of low-frequency reactance, FeNO<sub>50</sub> = exhaled NO level at flow of 50 ml/s, J'awNO = bronchial NO maximal flux adjusted for trumpet shaped airways and axial diffusion, CANO(TMAD) = alveolar fraction of exhaled NO adjusted for trumpet shaped airways and axial diffusion

Values are means ± SD or median (range).

Table 2. Correlation coefficients of NO levels with pulmonary function values

	CANO(TMAD)	J'awNO	FeNO <sub>50</sub>
Pre-bronchodilator			
%FEV <sub>1</sub>	-0.18	-0.03	-0.12
%FEF <sub>25-75%</sub>	-0.09	-0.05	-0.10
Rrs20	0.22	-0.17	-0.05
Rrs5-Rrs20	<b>0.35<sup>†</sup></b>	-0.09	0.11
Xrs5	<b>-0.31*</b>	-0.05	-0.19
AX	<b>0.35<sup>†</sup></b>	-0.03	0.14
Reversibility			
ΔFEV <sub>1</sub>	<b>0.35<sup>†</sup></b>	-0.007	0.09
ΔFEF <sub>25-75%</sub>	<b>0.31*</b>	0.09	0.21
ΔRrs20	-0.23	-0.007	-0.01
Δ(Rrs5-Rrs20)	-0.22	0.05	0.01
ΔXrs5	<b>-0.24*</b>	-0.16	<b>-0.25*</b>
ΔAX	<b>-0.31*</b>	-0.16	-0.10

\*:  $p \leq 0.05$ , <sup>†</sup>:  $p < 0.01$ , Correlation coefficients of Spearman's correlation coefficients are shown.

Δ = (post-bronchodilator value minus pre-bronchodilator value) / pre-bronchodilator value, Rrs20 = resistance of the total respiratory system at 20 Hz, Rrs5 = Rrs at 5 Hz

Xrs5 = reactance at 5 Hz, AX = integrated area of low-frequency reactance,

CANO(TMAD) = alveolar fraction of exhaled NO adjusted for trumpet shaped airways and

axial diffusion, J'awNO = bronchial NO maximal flux adjusted for trumpet shaped

airways and axial diffusion, FeNO<sub>50</sub> = fraction of exhaled NO at 50 ml/sec




Figure 1